Pulmonary Edema Therapeutics Market by Type and Geography - Forecast and Analysis 2022-2026

The predicted value for the pulmonary edema therapeutics market from 2021 to 2026 is USD 339.45 million at a progressing CAGR of 3.06%.

This pulmonary edema therapeutics market forecast report extensively covers market segmentation by:

• Type - Cardiogenic pulmonary edema and non-cardiogenic pulmonary edema
• Geography - North America, Europe, Asia, and Rest of World (ROW)

What will the Pulmonary Edema Therapeutics Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Pulmonary Edema Therapeutics Market Size for the Forecast Period and Other Important Statistics

The pulmonary edema therapeutics market report offers information on several market vendors, including AbbVie Inc., ADVANZ PHARMA Corp., Apotex Inc., Bausch Health Companies Inc., CHIESI Farmaceutici SpA, CMP Pharma Inc., Johnson and Johnson, Lupin Ltd., Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., and Validus Pharmaceuticals LLC among others. Furthermore, our analysts have provided valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches for the coming years.

Pulmonary Edema Therapeutics Market: Key Drivers, Trends, and Challenges

The high prevalence of risk factors is notably driving the pulmonary edema therapeutics market growth, although factors such as adverse effects of available therapeutics may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the pulmonary edema therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Pulmonary Edema Therapeutics Market Driver

• The high prevalence of risk factors is one of the key drivers fueling the pulmonary edema therapeutics market growth.
• Pulmonary edema is one of the leading causes of death in adults living in developing countries.
• Heart failure is one of the most common causes of cardiogenic pulmonary edema, a condition in which the left ventricle is unable to pump the adequate volume of blood required to meet the needs of the body.
• Individuals that have been exposed to chemicals during industrial accidents or those that work in hazardous chemical-manufacturing companies are prone to developing lung diseases. Chemicals such as nitrogen dioxide, which do not easily dissolve in the body, do not show any early symptoms but can cause inflammation in the bronchioles and lead to fluid accumulation in the lungs.
• Trauma as a result of accidents is also responsible for pulmonary edema. Accident Injuries in the chest region damage the lungs by creating pressure in the alveolar fluid, resulting in pulmonary edema. Thus, the high prevalence of risk factors is a primary driving factor driving the growth of the global pulmonary edema market. 

Key Pulmonary Edema Therapeutics Market Trend

• The increasing use of biomarkers for disease diagnosis is one of the key pulmonary edema therapeutics market trends supporting market growth.
• A biomarker is a measurable indicator of a specific biological state or condition, including a pathogenic process.
• The detection of pulmonary edema through biomarkers is gaining prominence in recent diagnostic evaluations. Moreover, the evaluation of serum and cardiac markers is prominent in disease diagnosing. 
• The serum brain natriuretic peptide (BNP) or N-terminal-pro BNP (NT-pro-BNP) and plasma CD146 cardiac are the cardiac markers that are collected through blood tests. The elevated levels of these markers indicate the congestion of heart failure disease, which causes pulmonary edema.
• The ARDS makers include interleukin-1b, interleukin-6, and others. The elevated levels of these markers in blood represent the patients who have non-cardiogenic pulmonary edema. Hence, the use of these biomarkers is less expensive than other evaluation tests, which further increases patient adherence. Such a cost-effective factor will propel the pulmonary edema therapeutics market growth during the forecast period.

Key Pulmonary Edema Therapeutics Market Challenge

• Adverse effects of available therapeutics is one of the factors challenging the pulmonary edema therapeutics market growth.
• The common adverse effects exhibited by pulmonary edema therapeutics include mild adverse events such as headache, fever, chills, nausea, and vomiting. 
• For instance, DEMADEX is used to treat hypertension and edema caused by heart, liver, or kidney diseases. The common side effects of DEMADEX include frequent urination, sore throat, constipation, weakness, and others. Meanwhile, the serious adverse effects include dehydration, chest pain, blood vomiting, weight loss, difficulty in breathing or swallowing, and skin rashes. 
• Despite being highly efficacious, strong adverse effects of pulmonary edema therapeutics are expected to hinder patient adherence to the treatment regimen, which will act as a barrier to the pulmonary edema therapeutics market growth during the forecast period. 

This pulmonary edema therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global pulmonary edema therapeutics market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the pulmonary edema therapeutics market during the forecast period.

Who are the Major Pulmonary Edema Therapeutics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• AbbVie Inc.
• ADVANZ PHARMA Corp.
• Apotex Inc.
• Bausch Health Companies Inc.
• CHIESI Farmaceutici SpA
• CMP Pharma Inc.
• Johnson and Johnson
• Lupin Ltd.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Validus Pharmaceuticals LLC

 

This statistical study of the pulmonary edema therapeutics market encompasses successful business strategies deployed by the key vendors. The pulmonary edema therapeutics market is concentrated and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Product Insights and News

• Abbvie.com - The company offers FIRAZYR that is a bradykinin B2 receptor antagonist indicated for the treatment of acute attacks of hereditary angioedema in adults 18 years of age and older.
• Advanzpharma.com - The company offers Dyrenium for the treatment of Edema and Hypertension.
• Apotex.com - The company offers Apo-Varenicline for the treatment of pulmonary edema.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The pulmonary edema therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Pulmonary Edema Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the pulmonary edema therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Pulmonary Edema Therapeutics Market?

For more insights on the market share of various regions Request for a FREE sample now!

35% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for pulmonary edema therapeutics in North America. Market growth in this region will be faster than the growth of the market in Rest of World (ROW).

The high prevalence of risk factors and increasing approval of drugs to treat pulmonary edema will facilitate the pulmonary edema therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The outbreak of COVID-19 had a negative impact on the pulmonary edema therapeutics market in North America. However, by January 2021, most lockdown restrictions in various countries had been relaxed to some extent, which led to the resumption of business activities with a full workforce, which will drive the demand for pulmonary edema therapeutics in North America during the forecast period.

What are the Revenue-generating Type Segments in the Pulmonary Edema Therapeutics Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The pulmonary edema therapeutics market share growth by the cardiogenic pulmonary edema segment will be significant during the forecast period. Cardiogenic pulmonary edema is caused by increased pressure in the heart. It occurs when the diseased left ventricle is unable to pump out enough blood, which it receives from the lungs. As a result, the pressure increases inside the left atrium, followed by a pressure increase in the veins and capillaries of the lungs, causing fluids to be pushed through the capillary walls into the air sacs. The growth of this segment is mainly driven by the high prevalence of cardiovascular diseases such as carotid artery disease, cardiomyopathy, heart valve problems, and hypertension. 

This report provides an accurate prediction of the contribution of all the segments to the growth of the pulmonary edema therapeutics market size and actionable market insights on post COVID-19 impact on each segment.

 

Pulmonary Edema Therapeutics Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 3.06%
Market growth 2022-2026	$ 339.45 million
Market structure	Concentrated
YoY growth (%)	2.55
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 35%
Key consumer countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	AbbVie Inc., ADVANZ PHARMA Corp., Apotex Inc., Bausch Health Companies Inc., CHIESI Farmaceutici SpA, CMP Pharma Inc., Johnson and Johnson, Lupin Ltd., Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., and Validus Pharmaceuticals LLC
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Pulmonary Edema Therapeutics Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive pulmonary edema therapeutics market growth during the next five years
• Precise estimation of the pulmonary edema therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the pulmonary edema therapeutics industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of pulmonary edema therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch